Bright Peak Therapeutics Archives

Home / Posts tagged Bright Peak Therapeutics

Bright Peak Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of BPT567, a First-in-Class Bifunctional PD1-IL18 Immunoconjugate

– BPT567 is the first bifunctional PD1-IL18 immunoconjugate to enter clinical development – – Phase 1/2a study will evaluate BPT567 in patients with locally advanced/unresectable or metastatic solid tumors – BASEL, Switzerland and SAN DIEGO, Oct. 17, 2024 (Korea Bizwire) – Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies [...]

Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-IL18 Immunoconjugate Program Into Clinical Trials

– Lead Program, BPT567, will be the first PD1-IL18 immunoconjugate to enter the clinic; Phase 1/2a study in solid tumors expected to begin in 2H 2024 – – Financing led by Johnson & Johnson with participation by new and existing investors – BASEL, Switzerland and SAN DIEGO, June 11, 2024 (Korea Bizwire) – Bright Peak Therapeutics, [...]

Bright Peak Therapeutics Presents New Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

BPT567, a first-in-class PD1-IL18 immunoconjugate designed to enable cis-signaling and preferentially activate intratumoral PD1+IL18R+ effector T cells induces potent preclinical antitumor activity SAN DIEGO and BASEL, Switzerland, Apr. 9 (Korea Bizwire) — Bright Peak Therapeutics, a biotechnology company developing multifunctional immunotherapies for cancer and autoimmune disease, today announced the presentation of new data characterizing the [...]

Bright Peak Therapeutics to Present Innovative Best-in-Class and Multifunctional Regulatory T Cell (Treg) Enhancers at the 10th International Conference on Autoimmunity: Mechanisms and Novel Treatments

SAN DIEGO and BASEL, Switzerland, Oct. 20 (Korea Bizwire) — Bright Peak Therapeutics, a privately held biotechnology company developing next-generation multifunctional precision immunotherapies, today announced the presentation of two posters showcasing the potential of its unique chemical protein engineering platform at the 10th International Conference on Autoimmunity: Mechanisms and Novel Treatments taking place October 20-25, 2022, [...]

Bright Peak Therapeutics Announces Formation of World Class Immuno-Oncology Scientific Advisory Board

SAN DIEGO & BASEL, Switzerland, Oct. 18 (Korea Bizwire) — Bright Peak Therapeutics, a privately held biotechnology company leveraging a revolutionary chemical protein engineering platform to develop next-generation multifunctional cytokine-based immunotherapies, today announced the formation of a Scientific Advisory Board (“SAB”) comprised of world-renowned experts in immuno-oncology basic, translational and clinical research. “Bright Peak is [...]

Bright Peak Therapeutics Announces the Appointment of Cancer Immunotherapy Leader Jon Wigginton, M.D., as President of Research and Development

SAN DIEGO and BASEL, Switzerland, Aug. 22 (Korea Bizwire) — Bright Peak Therapeutics, a biotechnology company developing next-generation precision immunotherapies to treat cancer and autoimmune disease, today announced the appointment of Jon Wigginton, M.D., as its President of Research and Development. “With a lifelong dedication to improving the lives of patients with cancer, Dr. Wigginton [...]

Bright Peak Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting

SAN DIEGO and BASEL, Switzerland, April 4 (Korea Bizwire) — Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced the acceptance of one oral presentation and two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting taking place April 8-13, 2022, in New [...]

Bright Peak Therapeutics Appoints Leena Gandhi, M.D., Ph.D., to its Board of Directors

SAN DIEGO and BASEL, Switzerland, Feb. 28 (Korea Bizwire) — Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it has appointed Leena Gandhi, M.D., Ph.D., to its Board of Directors. Dr. Gandhi is a distinguished physician-scientist with a focus on cancer immunotherapy and early [...]

Bright Peak Therapeutics Appoints Jacob Chacko, M.D., as Chair of its Board of Directors

SAN DIEGO and BASEL, Switzerland, Nov. 29 (Korea Bizwire) — Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it has appointed Jacob Chacko, M.D., as Chair of its Board of Directors. Dr. Chacko currently serves as President, CEO and member of the Board of [...]

Bright Peak Therapeutics Licenses Rights to Livzon’s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted Immunocytokines

SAN DIEGO and BASEL, Switzerland, Nov. 16 (Korea Bizwire) — Bright Peak Therapeutics, Inc., a biotechnology company developing next-generation cytokine immunotherapies, today announced that it has entered into a license agreement with Livzon Mabpharm, Inc. (“Livzon”), a subsidiary company of Livzon Pharmaceutical Group, to use LZM009, Livzon’s proprietary anti-PD-1 monoclonal antibody currently in late-stage clinical [...]